Skip to main content

Table 2 Fasting PCSK9 and lipid levels pre- and post-atorvastatin treatment

From: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

  Baseline Treatment % Change
PCSK9 (μg/mL) 5.88 ± 1.70 6.32 ± 2.29* 7.40 ± 25.3
Total cholesterol 5.82 ± 0.76 4.37 ± 0.62*** -25.0 ± 9.06
Triglycerides 1.50 ± 0.56 1.26 ± 0.58** -16.2 ± 28.0
HDL cholesterol 1.32 ± 0.26 1.43 ± 0.30*** 8.03 ± 13.2
LDL cholesterol 3.82 ± 0.67 2.37 ± 0.53*** -38.0 ± 10.3
TC/HDLC Ratio 4.53 ± 0.89 3.17 ± 0.63*** -30.1 ± 9.79
  1. Significance comparing baseline and treatment by Wilcoxon's signed rank test (n = 40). Values expressed as μmol/L except where indicated.
  2. *p < 0.05, **p < 0.001, ***p < 0.0001